Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Releases Q1 Economic Report On Pharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

China's National Development and Reform Commission (NDRC) has released the Q1 2008 report on the economic progress of key industries. The economic profit of the pharmaceutical industry increased 18.6 percent compared to the same period last year. Chemical medicine output hit 783,000 tonnes while patented Chinese medicine reached 273,000 tonnes, with increases of 11.7 and 10.2 percent, respectively. In the first two months of this year, the pharmaceutical industry realized a profit of 9.41 billion yuan, 50.1 percent higher than the same period in 2007. NDRC forecasts that the growth in output and sales will continue to maintain a level of over 20 percent for this year. With the government's growing investment in health care and tighter industrial supervisory policies, observers are positive about the pharmaceutical industry's outlook. (Click here for more - Chinese Language)

You may also be interested in...

What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts